BIVI Stock Summary and Trading Ideas (Biovie | NASDAQ:BIVI)

BioVie Inc is a clinical-stage company developing drug therapies for the treatment of neurological and neurodegenerative disorders and liver disease. Its therapeutic areas include Alzheimer's, Parkinson's, Long COVID, Ascites, Longevity, and Epigenetics. In liver disease, its investigational drug candidate BIV201 (continuous infusion terlipressin) was granted FDA Fast Track status and FDA Orphan Drug designation for ascites due to all etiologies except cancer. BIV201 is being evaluated as a treatment option for patients suffering from life-threatening complications of liver cirrhosis and ascites due to hepatitis, nonalcoholic steatohepatitis, and alcoholism.

Biovie trades on the NASDAQ stock market under the symbol BIVI.

As of October 1, 2026, BIVI stock price declined to $1.47 with 262,561 million shares trading.

BIVI has a beta of -0.08, meaning it tends to be less sensitive to market movements. BIVI has a correlation of 0.00 to the broad based SPY ETF.

BIVI has a market cap of $12.76 million. This is considered a Sub-Micro Cap stock.

In the last 3 years, BIVI traded as high as $582.00 and as low as $.82.

The top ETF exchange traded funds that BIVI belongs to (by Net Assets): VXF.

BIVI has underperformed the market in the last year with a price return of -22.6% while the SPY ETF gained +15.8%. BIVI has also underperformed the stock market ETF in the last 3 month and 2 week periods returning -24.2% and -14.5%, respectively, while the SPY returned +2.6% and +1.6%, respectively.

BIVI support price is $1.42 and resistance is $1.62 (based on 1 day standard deviation move). This means that using the most recent 20 day stock volatility and applying a one standard deviation move around the stock's closing price, stastically there is a 67% probability that BIVI shares will trade within this expected range on the day.